A research team led by Luigi Naldini at the San Raffaele Telethon Institute for Gene Therapy (SR-Tiget) reported a new gene-editing strategy—called SMArT—that aims to improve precision and safety of CRISPR-Cas9 editing in hematopoietic stem cells. The approach targets a key barrier for broader clinical use: minimizing unintended edits while maximizing the fraction of stem cells bearing the intended functional change. The work focuses on engineering hematopoietic stem cells with enhanced control using CRISPR, aiming to reduce risks associated with off-target and undesirable on-target outcomes. The platform is positioned as a step toward improved therapeutic reliability for genome-editing programs. If validated further, such improvements could reduce regulatory friction and widen the set of diseases addressable by ex vivo edited blood stem cell therapies.